Company Profile
Achieve Life Sciences Stock Price, News & Catalysts
- Ticker:
- ACHV
- Exchange:
- NASDAQ
- Sector:
- Life Science Tools
- Location:
- United States
Stock performance
7.50 USD (-1.19%)
Close
Last updated: August 17, 2026
516M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ACHV closed down 1.19% at $7.50. No new same-company headline was identified in the current news window.
Company overview
Nicotine Dependence Company
Achieve Life Sciences develops cytisinicline as a treatment for nicotine dependence and smoking cessation.
Cytisinicline
Cytisinicline is a plant-derived partial agonist of the nicotinic acetylcholine receptor and is intended as a shorter-course alternative to existing prescription therapies.
Phase 3 Evidence
The ORCA-2 and ORCA-3 studies demonstrated higher continuous abstinence rates than placebo, including in participants previously treated with varenicline or bupropion.
Manufacturing Transition
After FDA inspection findings at a prior third-party facility affected the NDA review, Achieve moved finished-drug-product manufacturing to U.S.-based Adare Pharma Solutions. The FDA's complete response letter did not identify deficiencies in cytisinicline's clinical efficacy or safety.
Future catalysts
- Resubmission of the cytisinicline NDA with Adare as the finished-drug-product manufacturer in the fourth quarter of 2026.
- Potential FDA approval of cytisinicline in the first half of 2027, followed by a U.S. commercial launch.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Achieve Life Sciences (ACHV)?
Achieve Life Sciences (ACHV) most recently closed at 7.50 USD, a -1.19% move versus the previous session.
What is the market cap of Achieve Life Sciences (ACHV)?
Achieve Life Sciences currently has a market capitalization of 516M USD on BioPharmSignal.
What does Achieve Life Sciences do?
Nicotine Dependence Company Achieve Life Sciences develops cytisinicline as a treatment for nicotine dependence and smoking cessation. Cytisinicline Cytisinicline is a plant-derived partial agonist of the nicotinic acetylcholine receptor and is intended as a shorter-course alternative to existing prescription therapies. Phase 3 Evidence The ORCA-2 and...
On which exchange is ACHV stock listed?
Achieve Life Sciences (ACHV) is associated with NASDAQ, United States, Life Science Tools.
What is ORCA-2?
Phase 3 Evidence The ORCA-2 and ORCA-3 studies demonstrated higher continuous abstinence rates than placebo, including in participants previously treated with varenicline or bupropion.
Which conditions is Achieve Life Sciences targeting with ORCA-2?
Nicotine Dependence Company Achieve Life Sciences develops cytisinicline as a treatment for nicotine dependence and smoking cessation. Cytisinicline Cytisinicline is a plant-derived partial agonist of the nicotinic acetylcholine receptor and is intended as a shorter-course alternative to existing prescription therapies. Phase 3 Evidence The ORCA-2 and...
How does Achieve Life Sciences describe recent progress with ORCA-2?
Resubmission of the cytisinicline NDA with Adare as the finished-drug-product manufacturer in the fourth quarter of 2026. Potential FDA approval of cytisinicline in the first half of 2027, followed by a U.S. commercial launch.
What is ORCA-3?
Phase 3 Evidence The ORCA-2 and ORCA-3 studies demonstrated higher continuous abstinence rates than placebo, including in participants previously treated with varenicline or bupropion.